loading...

Community-Acquired Bacterial Pneumonia Symptom Diary (PneumoPRO©)

FNIH - Foundation for the National Institutes of Health

Distributed by Mapi Research Trust

ProQolid

Distributed by Mapi Research Trust

Basic description

  • Published in 2017
  • Developed by the FNIH Biomarkers Consortium CABP ABSSSI Project Team to measure efficacy outcomes from a patient perspective in Community-Acquired Bacterial Pneumonia (CABP) clinical trials
  • As per confirmation from the the FNIH, the PneumoPRO© can also be used in Hospital-Acquired Bacterial Pneumonia (HABP) indications
  • The PneumoPRO© has been submitted to the FDA COA Qualification Program
Authors

FNIH - Foundation for the National Institutes of Health

Copyright
© 2017 Foundation for the National Institutes of Health
Objective
To measure patient-reported symptoms and effects on functioning of CABP, as an endpoint in clinical trials of antibacterial drugs
Therapeutic area
  • Respiratory Tract Diseases
  • Infections
Therapeutic indication

Pneumonia, Bacterial

Community-Acquired Bacterial Pneumonia (CABP) and Hospital-Acquired Bacterial Pneumonia (HABP)
Type of Clinical Outcome Assessment (COA)
  • pro PRO
Original language(s)
  • English for the USA
Bibliographic reference(s) of the original questionnaire

Signs, Symptoms, And Existing Patient Reported Outcome (PRO) Measures In Community-Acquired Bacterial Pneumonia (CABP): A Comprehensive Literature Review. Cimms TA, Howard K, Portalupi S, Saretsky TL, Hoffmann SC, Crawley JA, Lorens L, Powers JH, The FNIH Biomarkers Consortium CABP ABSSSI Project Team. Presented at ISPOR 19th Annual International Meeting May, 2014, Montreal, QC, Canada (Abstract)

Development of a new Patient-Reported Outcome (PRO) Measure for Community-Acquired Bacterial Pneumonia (CABP). Howard K, Portulapi S, Hoffmann SC, Crawley J, Llorens L, Cimms TA, Powers JH, The FNIH Biomarkers Consortium CABP ABSSSI Project Team. Presented at ISPOR 19th Annual International Meeting May, 2014, Montreal, QC, Canada (Abstract)

Community-Acquired Bacterial Pneumonia (CABP): Development of A New Patient-Reported Outcome (PRO) FNIH Biomarkers Consortium CABP ABSSSI Project Team. Howard K, Clifford S, Powers JH, Saretsky T, Hoffmann SC, Llorens L, Talbot GH, Cimms TA. Presented at ISPOR 20th Annual International Meeting May 16-20, 2015, Philadelphia, PA, USA (Abstract)

Access this questionnaire

Please proceed below

Login SIGN up free

Contact and conditions of use

Authors

FNIH - Foundation for the National Institutes of Health

Contact information

Mapi Research Trust
PROVIDE™
27 rue de la Villette
69003 Lyon
France
Phone: +33 (0)4 72 13 66 66

Conditions of use

Students, physicians, clinical practice, not-funded academic users

You may access the questionnaire and/or its available translations directly (see tutorial). Should you not see the Download button, please contact us.

Funded academic users, healthcare organizations, commercial users & IT companies

Fees may apply to your project. Submit your request (see tutorial). Our PROVIDE team will get back to you with the needed information and license agreement in a timely manner.

Review copy

Examination copies can only be used for the limited purpose of examining the suitability of the Questionnaire for subsequent research and/or clinical use, and cannot be used in research or in clinical practice or distributed to others.
You are not authorized to modify, retype, translate, copy or otherwise duplicate the Questionnaire except with the further and prior written permission of Mapi Research Trust / the developers / copyright holders / distributors.

Languages

Original language(s)

  • English for the USA

Translations

The list of available translations is subject to constant changes and may not be exhaustive. It is provided for information only. Some recently produced translations may not be included in the list below yet. Please do check the status of available translations with Mapi Research Trust / the developers / copyright holders / distributors.

Also, the listed translations may not have undergone a full linguistic validation process and may require further work to be suitable for use in a study.

The author has selected Mapi/ICON Language Services as exclusive linguistic validation company to ensure the production of harmonized and consistent language versions.

For additional information on available translations of this instrument, or for a project involving new languages, please submit a request (tutorials available on our FAQs).

Conditions to translate

Commercial Users

Exclusive vendor for translation work for commercial users: Mapi/ICON Language Services

Academic Translation:

Not authorized

More information on translations

For information on, or permission to use the translations, please contact Mapi Research Trust.

Member Access

Subscribe to PROQOLID to access to full information

Access to advanced descriptions of Clinical Outcome Assessments (COAs)

A question? Contact us